Physician profile
Jack E Weaver
NPI 1902802101
$5,241.59
in general payments reported to CMS, 2019-2025
13 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 77% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $201 · 2021: $49.12 · 2022: $126 · 2023: $583 · 2024: $2,263 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,673 · Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,673.02 |
| Food and Beverage | $2,051.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,020.32 | 2021-2025 | Synchromedii, Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System |
| Boston Scientific Corporation | $670.48 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian, Spectra Wavewriter |
| Medtronic USA, INC. | $225.32 | 2019-2020 | |
| Pacira Therapeutics, INC. | $66.95 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $43.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.50 | 2020 | |
| Allergan, INC. | $36.95 | 2021 | |
| Medline Industries Lp | $34.17 | 2022-2024 | |
| Solventum Corporation | $30.46 | 2024 | Activ.A.C. |
| Vertex Pharmaceuticals Incorporated | $25.28 | 2025 | |
| Globus Medical, INC. | $22.60 | 2025 | Senza |
| Painteq LLC | $14.88 | 2023 | Painteq |
| Horizon Therapeutics Plc | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.